SCHEMBL952882

SCHEMBL952882

Nc1cc(-c2nc(-c3ccccc3)c(-c3ncn(C4CCCCO4)n3)s2)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.39
DBF4 Q9UBU7 3/20 0.39
TEK Q02763 1/20 0.34
ATR Q13535 2/20 0.34
CPT1A P50416 3/20 0.32
CPT2 P23786 2/20 0.32
MAPK14 Q16539 1/20 0.32
ADORA2A P29274 3/20 0.32
ADORA2B P29275 1/20 0.32
KHK P50053 1/20 0.32
PRCP P42785 1/20 0.31
RET P07949 1/20 0.31
ADORA1 P30542 2/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
PKM P14618 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3794471 0.85 ATR (0.34) CDC7DBF4ATRADORA2AADORA1
SCHEMBL3794474 0.84 ATR (0.33) CDC7DBF4ATRADORA2AADORA1
SCHEMBL953631 0.84 MAPK14 (0.40) CPT1AMAPK14
SCHEMBL953190 0.83 CDC7 (0.35) CDC7DBF4ATRCPT1ACPT2
SCHEMBL952063 0.82 EGFR (0.44) MAPK14
SCHEMBL954205 0.80 PTGS1 (0.36) ATRADORA2AADORA1
SCHEMBL954308 0.76 ADORA2A (0.36) MAPK14ADORA2AADORA1
SCHEMBL953238 0.75 CYP4F2 (0.31)
SCHEMBL952687 0.74 AKT1 (0.35) TEK
SCHEMBL953894 0.73 ADORA2A (0.34) ATRMAPK14ADORA2AADORA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885TEK 1749/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885TEK 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.